{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix C. Study Activities', 'Table note \"b.\" previously read:', 'End of Treatment Visit occurs within 7 days of documentation of the decision to', 'discontinue treatment and prior to subjects beginning any new anti-cancer therapy if', 'possible.', 'Has been changed to read:', 'End of Treatment Visit procedures should be done within 7 days of documentation of the', 'decision to discontinue treatment and prior to subjects beginning any new anti-cancer', 'therapy if possible.', 'Appendix C. Study Activities', 'Table note \"e.,\" first sentence previously read:', 'Cycle 1 Day 1 procedures do not need to be repeated if performed within 21 days of', 'randomization unless clinically indicated.', 'Has been changed to read:', 'Cycle 1 Day 1 procedures, with the exception of weight, do not need to be repeated if', 'performed within 21 days of randomization unless clinically indicated.', 'Appendix C. Study Activities', 'Table note \"n.\" previously read:', 'Echocardiogram will be performed to assess any pericardial effusion, if present, as well as', 'cardiac function (left ventricular ejection fraction, LVEF).', 'Has been changed to read:', 'Echocardiograms are required at Screening, Day 1 of each cycle starting C2D1, and EOT.', 'Screening echocardiogram will be performed within 7 business days of randomization to', '204']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'assess for the presence of any pericardial effusion as well as cardiac function (left', 'ventricular ejection fraction, LVEF). Subsequent echocardiograms should be performed', 'within -3 business days of dosing visit to assess for the presence of any pericardial', 'effusion. Additional echocardiogram monitoring may occur as clinically indicated during', 'the study.', 'Appendix C. Study Activities', 'Table note \"q.,\" seventh sentence previously read:', 'Scheduled tumor assessments will not be affected by delays in therapy and/or drug', 'holidays.', 'Has been changed to read:', 'Whenever possible, scheduled tumor assessments should not be affected by delays in', 'therapy and/or drug holidays. In some cases, mandatory dose delays due to toxicity will', 'lead to a gap between tumor assessment and dosing. In cases where this gap exceeds', '1 week, the TAMD should be contacted for guidance.', 'Appendix C. Study Activities', 'Table note \"t.\" previously read:', 'MRI/CT of the brain is only required at screening and when clinically indicated (e.g., if', 'CNS progression is suspected).', 'Has been changed to read:', 'MRI/CT of the brain is required at screening and when clinically indicated (e.g., if CNS', 'progression is suspected) thereafter.', '205']\n\n###\n\n", "completion": "END"}